InVivo Therapeutics Holdings Corporation (NVIVQ)
InVivo Therapeutics Holdings Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $0.37, up 12.12% on the session, giving a market capitalisation of $1.1M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of 0.0%. Its beta of 0.37 implies it has historically moved less than the broad market.
InVivo Therapeutics Holdings Corp. is a U.S.-based biotechnology and biomaterials company, engaged in both research and clinical development. The company's primary focus is on pioneering and commercializing biopolymer scaffolding devices specifically designed for the treatment of spinal cord injuries (SCI). Its flagship product under development is the Neuro-Spinal Scaffold implant, which is constructed from a blend of biocompatible and bioresorbable polymers. These polymers include Poly lactic-co-glycolic acid (PLGA), a material frequently found in dissolvable sutures that provides crucial biocompatible support for the scaffold, and Poly-L-Lysine, a positively charged polymer used to encourage cellular attachment. Founded in 2003, InVivo Therapeutics maintains its headquarters in Cambridge, Massachusetts.
InVivo Therapeutics Holdings Corporation is most often compared with the following Healthcare names: